• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Articles of Association
      • Auditor
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Articles of Association
      • Auditor
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
Home / Alzinova at Redeye Neurology (CNS) Seminar October 13th
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Company Presentation
  • The Share
    • Share Information
    • Largest Shareholders
    • Share Capital Development
    • Rights Issues / Företrädesemissioner
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Previous Nomination Committees
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact
Back to all presentations

Alzinova at Redeye Neurology (CNS) Seminar October 13th

Date: 2021-10-13

Our CEO, Kristina Torfgård, presented the company at the Redeye Neurology Seminar together with representatives from the other Swedish companies developing therapies to fight Alzheimer's disease.

View the presentation, in English.

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin